A study of ABBV-706 and atezolizumab for patients with previously untreated extensive stage small cell lung cancer

2 1 1 1

What is this study about?

This study is designed to evaluate the safety and effectiveness of a new treatment for individuals with Extensive Stage Small Cell Lung Cancer, which is a type of lung cancer that has spread to other parts of the body. The research aims to compare a combination of the experimental drug ABBV-706 and atezolizumab against the current standard treatments. The standard care options being compared include carboplatin and etoposide, which are medications typically given through an intravenous line, meaning they are delivered directly into a vein.

Participants in the study will receive their assigned medications through an intravenous infusion. The goal of the research is to determine the best dose of ABBV-706 to use in future larger studies and to see how well this combination works to control the disease compared to traditional therapy. The study will monitor how long the cancer remains stable without getting worse and how the body responds to the different treatment combinations.

Who Can Join the Study?

You must have a confirmed diagnosis of extensive stage small cell lung cancer, which is a type of lung cancer that has spread widely within the chest, and you must require first line therapy, meaning this is the first treatment you are receiving for this condition.
You must have an ECOG Performance Status of 0 or 1, which is a scale used by doctors to measure how well you can perform daily activities; a score of 0 or 1 means you are physically able to carry out most daily tasks and are generally mobile.
You must be able to safely receive a treatment plan that includes platinum-based chemotherapy, specifically a combination of two drugs called carboplatin and etoposide, along with a medicine called atezolizumab.
Your cancer must include measurable disease, meaning that the tumors are large enough and in locations that allow doctors to clearly see and track changes in their size using standard medical imaging rules known as RECIST v1.1.
If you have had radiation therapy in the past, any tumors in those areas can still be measured if they show signs of progression, which means the cancer is growing or spreading.
This study is open to both males and females.
You must fall within the specific age range defined for this study.

Who Cannot Join the Study?

People with mixed small cell lung cancer, which is a type of lung cancer that contains more than one specific type of small cell cancer cells, cannot join.
Anyone who has already received any type of treatment for limited-stage small cell lung cancer, which is cancer that is only found in one lung and has not spread to nearby lymph nodes, is not eligible.
People who have previously had systemic therapy, which is medicine that travels through the entire body via the bloodstream, for extensive-stage small cell lung cancer, which is cancer that has spread to other parts of the body, are excluded.
Individuals with active or symptomatic central nervous system metastases, meaning cancer that has spread to and is currently causing problems in the brain or spinal cord, cannot participate.
People with a history of interstitial lung disease, which is a group of conditions that cause scarring or inflammation in the lungs, or pneumonitis, which is inflammation of the lung tissue, are excluded if they needed treatment with systemic steroids (strong medicines used to reduce inflammation).
Anyone showing signs of active interstitial lung disease or pneumonitis on a chest CT scan, which is a detailed X-ray image of the chest used to look at the lungs, is not allowed to join.

Where you can join this trial?

Verified and Recommended Sites

Site Name	City	Country	Status
Samodzielny Publiczny Szpital Kliniczny Nr 4 W Lublinie	Lublin	Poland

Verified Sites

Site Name	City	Country	Status
Azienda Ospedaliera Universitaria Universita’ Degli Studi Della Campania Luigi Vanvitelli	Naples	Italy
Lungenfachklinik	Immenhausen	Germany

Other Sites

Site Name	City	Country
Istituto Oncologico Veneto	Padua	Italy
Hospital General Universitario Gregorio Maranon	Madrid	Spain
Hospital Universitario 12 De Octubre	Madrid	Spain
Az Maria Middelares Gent	Gent	Belgium
Grand Hopital De Charleroi	Charleroi	Belgium
Evangelische Lungenklinik Berlin Krankenhausbetriebs gGmbH	Berlin	Germany
Ospedale San Raffaele S.r.l.	Milan	Italy
Azienda Ospedaliero-Universitaria San Luigi Gonzaga	Orbassano	Italy
Universita’ Campus Bio-medico Di Roma	Rome	Italy
Hospital Clinic De Barcelona	Barcelona	Spain
Jessa Ziekenhuis	Hasselt	Belgium
Justus-Liebig-Universitaet Giessen	Giessen	Germany
CHC MontLegia	Liege	Belgium
Wielkopolskie Centrum Pulmonologii I Torakochirurgii Im. Eugenii I Janusza Zeylandow	Poznan	Poland
Ifxpak Iftwhvhc Fdowavvdxnxjn Oorqszeciaf	Rome	Italy
Ilolhbwv Cpsymo Dsfjorwzvrgewdxbh	L'hospitalet De Llobregat	Spain
Npbdhbfu Itcwwqre Ouqlicqra Iho Mfulz Sfqrfyjjwzeslmfatfjqqjjqgqdn Iamesnks Birwlhys	Cracow	Poland
Armxrci Uldnu Sgkydafvv Luejdq Dp Btzhwdv	Bologna	Italy
Htjanyef Umspescqxigkp dj A Cmkkvv	A Coruna Galicia	Spain

Trial status

Country	Status	Recruitment Start
Belgium	Recruiting	30.03.2026
Germany	Recruiting	30.03.2026
Italy	Not yet recruiting	30.03.2026
Poland	Recruiting	30.03.2026
Spain	Recruiting	30.03.2026

Trial locations

Investigated drugs:

ABBV-706 is an experimental therapy being tested in this study. It is a type of drug designed to target specific proteins on certain cells to help fight cancer.

Atezolizumab is a medication used to help the body’s immune system recognize and attack cancer cells. In this trial, it is being studied in combination with the experimental drug.

Carboplatin is a type of chemotherapy medication used to treat cancer by interfering with the ability of cancer cells to grow and divide.

Etoposide is a chemotherapy medication used to treat various types of cancer by preventing cancer cells from multiplying.

Small Cell Lung Cancer – This is a type of cancer that begins in the cells of the lung. It is characterized by the rapid growth and spread of abnormal cells. The disease often develops within the central part of the lungs near the large airways. As it progresses, these cells can move to nearby lymph nodes and other parts of the body. This condition is typically more aggressive than other forms of lung cancer.

Trial ID:

2024-517490-24-00

Protocol code:

M24-633

NCT ID:

NCT07155174

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

A study of ABBV-706 and atezolizumab for patients with previously untreated extensive stage small cell lung cancer

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?